Valuation: Cardiol Therapeutics Inc.

Market Cap 284M 201M 176M 166M 152M 19.24B 286M 1.99B 771M 9.83B 754M 738M 31.6B P/E 2026 *
-7.66x
P/E 2027 * -8.7x
Enterprise Value 269M 190M 167M 158M 144M 18.23B 271M 1.89B 731M 9.31B 714M 699M 29.93B EV / Sales 2026 *
-
EV / Sales 2027 * 278x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
09-23 Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial CI
09-23 Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx CI
08-12 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-12 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
05-07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
05-07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
05-07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
04-28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
04-28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
04-01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
04-01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
04-01 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
1 day-2.06%
1 week-9.85%
Current month-13.45%
1 month-11.85%
3 months+59.73%
6 months+39.18%
Current year+81.68%
1 week 2.35
Extreme 2.35
2.76
1 month 2.35
Extreme 2.35
3.23
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.11
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 19/01/2017
Director of Finance/CFO - 16/08/2018
Chief Operating Officer - 03/12/2020
Director TitleAgeSince
Director/Board Member - 15/12/2017
Director/Board Member - 19/01/2017
Chairman - 07/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 A Option

Chairman

25,000 0.0214%
9/8/26 A Option

Chairman

-25,000 0.0214%
8/28/26 A Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-9.85%+50.63%+101.69% 201M
+2.32%+6.01%+11.93%+37.83% 47.97B
-0.21%-0.22%+49.01%+36.21% 44.5B
-1.11%+5.10%+339.75%+617.40% 43.93B
+0.19%-0.69%+9.10%+97.17% 41.03B
-0.62%-1.11%+4.65%+46.13% 29.85B
-0.90%-2.59%+21.43%+146.80% 17.27B
-1.16%+7.45%+6.71% - 15.34B
+1.40%+0.49%+29.01%+47.89% 15.3B
+1.21%-4.71% - - 14.82B
Average -0.14%+1.43%+58.02%+141.39% 27.02B
Weighted average by Cap. +0.17%+2.86%+74.86%+163.30%

Financials

2026 *2027 *
Net sales - 984K 696K 611K 577K 526K 66.72M 991K 6.9M 2.67M 34.09M 2.61M 2.56M 110M
Net income -36.31M -25.68M -22.53M -21.28M -19.4M -2.46B -36.57M -255M -98.64M -1.26B -96.42M -94.33M -4.04B -36.46M -25.79M -22.63M -21.37M -19.48M -2.47B -36.72M -256M -99.05M -1.26B -96.82M -94.73M -4.06B
Net Debt -15.01M -10.61M -9.31M -8.8M -8.02M -1.02B -15.11M -105M -40.77M -520M -39.85M -38.99M -1.67B -10.26M -7.25M -6.36M -6.01M -5.48M -695M -10.33M -71.94M -27.86M -355M -27.23M -26.64M -1.14B
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
28/09/26 CA$2.380 -2.06% 17,170
25/09/26 CA$2.430 0.00% 125,207
24/09/26 CA$2.430 -2.41% 241,292
23/09/26 CA$2.490 -6.74% 396,819
22/09/26 CA$2.670 +1.14% 237,992
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.430CAD
Average target price
6.000CAD
Spread / Average Target
+146.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRDL Stock